安洛丁尼布诱导的1型糖尿病:一个病例报告
Jing Chen1, Daohan Xia1, Linqiu Ke1
1General Medicine Department, Chongqing General Hospital, Chongqing, China.
Frontiers in oncology
|April 17, 2025
概括
本案例研究报告了第一例1型糖尿病发生在接受洛替尼 (anlotinib) 治疗的患者身上,这是一种氨酸激酶抑制剂 (TKI). 建议在TKIs的患者进行早期血糖监测,以检测潜在的糖尿病.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 可以影响葡萄糖代谢,导致低血糖或高血糖.
- 安洛丁尼布是一种经批准用于非小细胞肺癌的口服多标TKI.
- 之前没有报告将安洛丁尼布或其他TKIs与1型糖尿病联系起来.
研究的目的:
- 报告1型糖尿病的第一个病例,该病例发生在用anlotinib治疗的患者身上.
- 为了探索anlotinib诱导的1型糖尿病的潜在机制.
- 为TKI治疗患者推监测指南.
主要方法:
- 一个81岁的男性肺癌患者的病例报告,他接受了anlotinib治疗.
- 关于TCI和葡萄糖代谢的文献综述.
- 分析患者的血糖,HbA1c和GADA水平.
主要成果:
- 患者在14次安洛提尼布治疗周期后发展为1型糖尿病.
- 被诊断为高的空腹血葡萄糖 (24.3 mmol/L),HbA1c (9.0%) 和GADA (>2000 IU/ml) 的患者.
- 文献综述探讨了将anlotinib与1型糖尿病联系起来的潜在机制.
结论:
- 安洛丁尼布可能会诱导1型糖尿病,这是一个新的副作用.
- 建议每周对血糖 (SMBG) 进行自我监测,以早期检测.
- 如果SMBG是不可行的,建议每月进行血葡萄糖和每季度HbA1c测试.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Dipeptidyl Peptidase 4 Inhibitors
128
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
128
Glucagon-like Receptor Agonists
264
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
264
Oral Hypoglycemic Agents: Biguanides and Glitazones
136
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
136
Insulin: Dosing Regimen and Adverse Effects
126
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
126
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K


